ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Biotechnology	7.70M	5.69M	13.81M
Biotechnology Growth	35.24%	-58.79%	-
Total	7.70M	5.69M	13.81M
Total Growth	35.24%	-58.79%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
PRC	386.00K	538.00K
PRC Growth	-28.25%	-
Total	386.00K	538.00K
Total Growth	-28.25%	-

Source: S&P Global Market Intelligence.